Blog Category

Generic Drugs: Why Is The Party Ending? 
Posted on Oct 20, 2017

The recent news that Novartis is closing its Colorado-based generics manufacturing facility brought back a few memories. A company spokesperson blamed “above-average pricing pressure“. The products were described as “oral…for a variety of conditions…expensive to make…and no longer competitive. Medicare Part D studies clearly show generic price deflation is quite real, even when some generic

Out-Licensing: How hard is it, really? 
Posted on Oct 12, 2017

Is out-licensing difficult? Yes, of course it is. But how difficult is it? Is this something which can be quantified? And, why would we want to quantify this anyway? These data from MedTrack show Partnerships in two therapeutic areas over time, by stage of development. Now we recognize that these data may have some issues. For

Valuation: Why Bother? 
Posted on Sep 21, 2017

This post is in response to a prospective client, who asked us about the required depth and complexity required in a financial model(s) when out-licensing. It’s an interesting question. So in this post, we’ll take a step back to examine this issue. The folks at Bain and Company recently published a short white paper entitled¬†How

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.